RT Journal Article
SR Electronic
T1 COVID-19-associated ARDS treated with DEXamethasone (CoDEX): Study design and rationale for a randomized trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.24.20139303
DO 10.1101/2020.06.24.20139303
A1 Bruno M. Tomazini
A1 Israel S. Maia
A1 Flavia R. Bueno
A1 Maria Vitoria A.O. Silva
A1 Franca Pellison Baldassare
A1 Eduardo Leite V. Costa
A1 Ricardo A.B. Moura
A1 Michele Honorato
A1 André N. Costa
A1 Alexandre B. Cavalcanti
A1 Regis Rosa
A1 Álvaro Avezum
A1 Viviane C. Veiga
A1 Renato D. Lopes
A1 Lucas P. Damiani
A1 Flávia R. Machado
A1 Otavio Berwanger
A1 Luciano C.P. Azevedo
A1 for the COALITION COVID-19 Brazil III Investigators
YR 2020
UL http://medrxiv.org/content/early/2020/06/26/2020.06.24.20139303.abstract
AB OBJECTIVES The infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) spreads worldwide and is considered a pandemic. The most common manifestation of SARS-CoV2 infection (Coronavirus disease 2019 - COVID-19) is viral pneumonia with varying degrees of respiratory compromise and up to 40% of hospitalized patients might develop Acute Respiratory Distress Syndrome (ARDS). Several clinical trials evaluated the role of corticosteroids in non-COVID-19 ARDS with conflicting results. We designed a trial to evaluate the effectiveness of early intravenous dexamethasone administration on the number of days alive and free of mechanical ventilation within 28 days after randomization in adult patients with moderate or severe ARDS due to confirmed or probable COVID-19.METHODS This is a pragmatic, prospective, randomized, stratified, multicenter, open-label, controlled trial including 350 patients with early-onset (less than 48h before randomization) moderate or severe ARDS, defined by the Berlin criteria, due to COVID-19. Eligible patients will be randomly allocated to either standard treatment plus dexamethasone (intervention group) or standard treatment without dexamethasone (control group). Patients in the intervention group will receive dexamethasone 20mg IV once daily for 5 days, followed by dexamethasone 10mg IV once daily for additional 5 days or until Intensive Care Unit (ICU) discharge, whichever occurs first. The primary outcome is ventilator-free days within 28 days after randomization, defined as days alive and free from invasive mechanical ventilation. Secondary outcomes are all-cause mortality rates at day 28, evaluation of the clinical status at day 15 assessed with a 6-level ordinal scale, mechanical ventilation duration from randomization to day 28, Sequential Organ Failure Assessment (SOFA) Score evaluation at 48h, 72h and 7 days and ICU-free days within 28.ETHICS AND DISSEMINATION This trial was approved by the Brazilian National Committee of Ethics in Research (Comissão Nacional de Ética em Pesquisa - CONEP) and National Health Surveillance Agency (ANVISA). An independent data monitoring committee will perform interim analyses and evaluate adverse events throughout the trial. Results will be submitted for publication after enrolment and follow-up are complete.ClinicalTrials.gov identifier NCT04327401Competing Interest StatementThis study is supported by Hospital Sirio-Libanes and by Aché pharmaceutical who provided the study drug, the drug logistics distribution to the study centers and insurance for the patients. Dr Berwanger reported research grants from AstraZeneca, Bayer, Amgen, Boehringer-Ingelheim, BMS, Servier, and Novartis. Dr. Lopes reported grants and personal fees from Bristol-Myers Squibb and Pfizer, personal fees from Boehringer Ingelheim and Bayer AG and grants from Amgen Inc, GlaxoSmithKline, Medtronic PLC, and Sanofi Aventis outside the submitted work. Dr. Avezum reported research grants from Bayer, Sanofi-Pasteur, Population Health Research Institute. Dr. Azevedo reported consulting fees from Halex-Istar and Baxter. Dr. Flavia Bueno reported consulting fees from Endpoint Health. All other authors report no conflicts of interest.Clinical TrialNCT04327401Funding StatementThis research is funded by Hospital Sirio-Libanes. The Aché pharmaceutical provided the study drug, the drug logistics distribution to the study centers and insurance for the study patients' but will have no participation or interfere with the trial design, enrolment, analysis, manuscript writing, or publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This trial was approved by the Brazilian National Committee of Ethics in Research (Comissão Nacional de Ética em Pesquisa - CONEP) and National Health Surveillance Agency (ANVISA)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is a protocol for an ongoing randomized controlled trial. We plan to upload the study dataset to a public database 3 months after database lock.